Читать книгу Recent Advances in Dialysis Therapy in Japan - Группа авторов - Страница 94

1Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, Wakai K, Wada A, Nitta K: An overview of regular dialysis treatment in Japan (as of 31 December 2013). Ther Apher Dial 2015;19:540–574.

2Nakao T, Inaba M, Abe M, Kaizu K, Shima K, Babazono T, Tomo T, Hirakata H, Akizawa T; Japanese Society for Dialysis Therapy: Best practice for diabetic patients on hemodialysis 2012. Ther Apher Dial 2015;19(suppl 1):40–66.

3Shima K, Komatsu M, Kawahara K, Minaguchi J, Kawashima S: Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis. Nephrology 2010;15:632–638.

4Ricks J, Molnar MZ, Kovesdy CP, Shah A, Nissenson AR, Williams M, Kalantar-Zadeh K: Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes 2012;61:708–715.

5Nakagami T; DECODA Study Group: Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47:385–394.

6Abe M, Matsumoto K: Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes? Nat Clin Pract Nephrol 2008;4:482–483.

7Abe M, Kalantar-Zadeh K: Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol 2015;11:302–313.

8Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y: Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007;18:896–903.

9Okada T, Nakao T, Matsumoto H, Shino T, Nagaoka Y, Tomaru R, Wada T: Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med 2007;46:807–814.

10Isshiki K, Nishio T, Isono M, Makiishi T, Shikano T, Tomita K, Nishio T, Kanasaki M, Maegawa H, Uzu T; Lake Biwa Clinical Dialysis Meeting: Glycated albumin predicts the risk of mortality in type 2 diabetic patients on hemodialysis: evaluation of a target level for improving survival. Ther Apher Dial 2014;18:434–442.

11Inaba M, Maekawa K, Okuno S, Imanishi Y, Hayashino Y, Emoto M, Shoji T, Ishimura E, Yamakawa T, Nishizawa Y: Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysis. Clin Nephrol 2012;78:273–280.

12Freedman BI, Andries L, Shihabi ZK, Rocco MV, Byers JR, Cardona CY, Pickard MA, Henderson DL, Sadler MV, Courchene LM, Jordan JR, Balderston SS, Graham AD, Mauck VL, Russell GB, Bleyer AJ: Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011;6:1635–1643.

13Abe M, Okada K, Soma M: Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011;12:57–69.

14Chacra A, Gantz I, Mendizabal G, Durlach L, O’Neill EA, Zimmer Z, Suryawanshi S, Engel SS, Lai E: A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment. Int J Clin Pract DOI: 10.1111/ijcp.12955.

15Asai S, Ohta A, Kato H, Sada Y, Nagai Y, Kondo A, Sasaoka T, Tanaka Y: Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes. Endocr J 2014;61:1213–1220.

16Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M: Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J 2013;60:733–742.

17Odawara M, Kadowaki T, Naito Y: Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study. J Diabetes Complications 2015;29:127–133.

18Takahara M, Shiraiwa T, Kaneto H, Katakami N, Matsuoka TA, Shimomura I: Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Endocr J 2012;59:1131–1136.

19Abe M, Kaizu K, Matsumoto K: Evaluation of the hemodialysis-induced changes in plasma glucose and insulin concentrations in diabetic patients: comparison between the hemodialysis and non-hemodialysis days. Ther Apher Dial 2007;11:288–295.

20Abe M, Okada K, Ikeda K, Matsumoto S, Soma M, Matsumoto K: Characterization of insulin adsorption behavior of dialyzer membranes used in hemodialysis. Artif Organs 2011;35:398–403.

Masanori Abe, MD, PhD

Division of Nephrology, Hypertension and Endocrinology

Department of Internal Medicine, Nihon University School of Medicine

30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo 173-8610 (Japan)

E-Mail abe.masanori@nihon-u.ac.jp